Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 24;59(11):1890.
doi: 10.3390/medicina59111890.

Shifting Paradigms: The Case of Autologous Reconstitution after an Upfront Matched Unrelated Hematopoietic Cell Transplantation for Severe Acquired Aplastic Anemia in a Child

Affiliations
Review

Shifting Paradigms: The Case of Autologous Reconstitution after an Upfront Matched Unrelated Hematopoietic Cell Transplantation for Severe Acquired Aplastic Anemia in a Child

Cécile Pochon et al. Medicina (Kaunas). .

Abstract

During the last few years, the therapeutic landscape of idiopathic aplastic anemia (IAA) has been profoundly revolutionized by the increased use of alternative transplant procedures, such that today hematopoietic cell transplantation (HCT) from a matched unrelated donor (MUD) has been suggested as a possible first line strategy in pediatric patients with severe IAA, in the absence of a matched related donor. However, in this particular context, outcomes and early and long-term toxicities remain to be determined, as compared to non-transplant procedures. While prospective trials are ongoing, we report here the case of a 12-year-old boy with IAA, receiving an upfront bone marrow HCT from a MUD, who experienced early graft rejection associated with autologous hematological recovery, which could induce remission of his hemopathy. This case offers the opportunity to discuss the challenges associated with these new transplant paradigms and provides a brief review of the literature regarding the issue of autologous recoveries after allogeneic HCT in IAA.

Keywords: MUD HCT; autologous reconstitution; graft failure; severe aplastic anemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient clinical course after BMT. Abbreviations: G-CSF: granulocytic stem cell factor; HCT: hematopoietic cell transplantation. Figure created with BioRender.com.

Similar articles

References

    1. Peffault de Latour R., Kulasekararaj A., Iacobelli S., Terwel S.R., Cook R., Griffin M., Constantijn J.M., Halkes M.D., Christian Recher M.D., Fiorenza Barraco M.D., et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N. Engl. J. Med. 2022;386:11–23. doi: 10.1056/NEJMoa2109965. - DOI - PubMed
    1. Kulasekararaj A.G., Hill A., Rottinghaus S.T., Langemeijer S., Wells R., Gonzalez-Fernandez F.A., Gaya A., Lee J.W., Gutierrez E.O., Piatek C.I., et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: The 302 study. Blood. 2019;133:540–549. doi: 10.1182/blood-2018-09-876805. - DOI - PMC - PubMed
    1. Lee J.W., Sicre de Fontbrune F., Wong Lee Lee L., Pessoa V., Gualandro S., Füreder W., Ptushkin V., Rottinghaus S.T., Volles L., Shafner L., et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood. 2019;133:530–539. doi: 10.1182/blood-2018-09-876136. - DOI - PMC - PubMed
    1. Risitano A.M., Röth A., Soret J., Frieri C., de Fontbrune F.S., Marano L., Alashkar F., Benajiba L., Marotta S., Rozenberg I., et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: An open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8:e344–e354. doi: 10.1016/S2352-3026(21)00028-4. - DOI - PubMed
    1. Risitano A.M., Peffault de Latour R. How we(‘ll) treat paroxysmal nocturnal haemoglobinuria: Diving into the future. Br. J. Haematol. 2022;196:288–303. doi: 10.1111/bjh.17753. - DOI - PMC - PubMed

Supplementary concepts